A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer
Status:
Active, not recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
PEACOCC is a multi-centre, single arm, single stage phase II trial. The overall aim is to
determine whether treatment with pembrolizumab is effective in patients with advanced clear
cell gynaecological cancer.